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incidence
Malignant pleural mesothelioma (MPM) is a rare tumor. The
incidence is 1.25/100 000 in Great Britain and 1.1/100 000 in
Germany. Within the next 20 years the incidence is estimated to
double in many countries. Exposure to asbestos is a well-
established etiological factor for MPM, with occupational
exposure having been documented in 70%–80% of those
affected.
diagnosis
Patients typically present with shortness of breath due to
pleural effusion or chest pain in a more advanced stage. The
diagnosis is usually suggested by imaging studies (unilateral
pleural thickening; pleural effusion). An occupational history
must be obtained.
Cytological examination of the effusion can be diagnostic,
but often shows equivocal results. Therefore, histology,
including immunohistochemistry, is the gold standard. Video-
assisted thoracoscopy or open pleural biopsy in a fused pleural
space may be necessary to provide sufficient material for
accurate histological diagnosis. There are three main
histological types (epithelial, sarcomatous and mixed), with
60% being epithelial.
Recent data suggest the possible contribution of serum
mesothelin-related proteins and osteopontin as useful markers
to support the diagnosis of mesothelioma; however, the precise
role of these markers is yet to be defined.
staging and risk assessment
Clinical staging is based on a thoracic CT scan; however, the
translation of the images into TNM (tumor–node–metastasis)
stages is often not conclusive. Mediastinoscopy and video-
assisted thoracoscopy may be useful in determining the stage.
Accurate initial staging is essential to provide both prognostic
information and guidance on the most appropriate therapeutic
options. Several different staging systems exist; among them is
the international staging system for MPM, which
emphasizes the extent of disease after surgery in a traditional
TNM system and stratifies patients into similar prognostic
categories (Table 1).
The Cancer and Leukemia Group B and the European
Organization for Research and Treatment of Cancer prognostic
scores may be used. They include performance status, age,
histological type, weight loss and white blood count.
MPM rarely metastasizes to distant sites but most patients
present with locally advanced disease. The use of PET scan to
rule out extra-thoracic metastasis is under investigation and
findings seem promising.
treatment
surgery
Different surgical procedures have been tested with varying
degrees of success.
Extra-pleural pneumonectomy (EPP) with resection of the
hemidiaphragm and the pericardium en bloc has the potential
for a radical treatment and this approach is generally combined
with neoadjuvant chemotherapy and/or adjuvant radiotherapy.
Surgery, the appropriateness of which is still under
consideration, should only be performed on selected patients
by experienced thoracic surgeons in the context of
a multidisciplinary team and preferably as part of a clinical trial
[III, A]. Selection criteria include good performance status,
earlier stage disease with not more than localized involvement
of the thoracic wall and adequate cardiopulmonary function.
The inclusion of patients with N2 or sarcomatoid disease is
controversial. Pleurectomy/decortication may be indicated for
elderly patients, at early stages or when EPP would leave
macroscopic tumor behind.
To optimally palliate patients from dyspnea and pain, local
procedures to control pleural effusion includes parietal
pleurectomy or talc pleurodesis.
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radiotherapy
The use of hemithoracic radiotherapy has been limited because
of severe side effects of irradiation of the underlying lung.
Conventional radiotherapy dose can be delivered locally as
a palliative measure for pain management. Modern
radiotherapy techniques allow for delivering high-dose
radiotherapy in an attempt to improve local control after
extrapleural pneumonectomy. Caution must be exercised
regarding the exposure of the contralateral lung to low-dose
irradiation. Mesothelioma invades the tracts made by chest
instrumentation. However, prophylactic radiotherapy to reduce
the incidence of port metastases is controversial and not
routinely applied.
chemotherapy
Platinum analogues, doxorubicin and some antimetabolites
(methotrexate, raltitrexed and pemetrexed) have shown modest
single agent activity [III, B].
The combinations of both pemetrexed/cisplatin and
raltitrexed/cisplatin have been shown to improve survival as
well as lung function and symptom control in comparison with
cisplatin alone in randomized trials [II, A]. The combination
pemetrexed/carboplatin is an alternative effective therapy [III,
A].
A phase III trial evaluated second-line pemetrexed versus best
supportive care in patients not previously exposed to this agent
and found a longer time to disease progression in the
chemotherapy arm.
If extrapleural pneumonectomy is planned, platinum-based
neoadjuvant or adjuvant combination chemotherapy should be
considered.
response evaluation
Response evaluation using CT scan is recommended after two
to three chemotherapy cycles and the modified RECIST criteria
should be applied.
follow-up
Follow-up consists of clinical evaluation, with particular
attention to symptoms or chest wall recurrence, and a thoracic
CT scan as needed.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justified standard clinical practice by the expert authors and the
ESMO faculty.
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Table 1. International staging system for malignant pleural
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Stage TNM Comments
Ia T1a N0 M0 Primary tumor limited to
ipsilateral parietal pleura
Ib T1b N0 M0 As stage Ia plus focal
involvement of visceral
pleura
II T2 N0 M0 As stage Ia or Ib plus
confluent involvement of
diaphragm or visceral
pleura or involvement of
the lung
III Any T3 M0, any N1 M0,
any N2 M0
Locally advanced tumor;
ipsilateral,
bronchopulmonary or
hilar lymph node
involvement; subcarinal or
ipsilateral mediastinal
lymph node involvement
IV Any T4, any N3, any M1 Locally advanced technically
unresectable tumor;
contralateral mediastinal,
internal mammary and
ipsilateral or contralateral
supraclavicular lymph
node involvement; distant
metastases
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